Abstract：
OBJECTIVE: To determine the extent to which nephrology journals recommend and require reporting guideline adherence and clinical trial registration.
BACKGROUND: Despite a rising disease burden, research published on chronic kidney disease (CKD) and the field of nephrology has failed to keep pace and is limited. To improve the quality of research in the field of nephrology, reporting guidelines have been developed to minimize such deficits in research quality. However, the extent to which nephrology journals require and use reporting guidelines in addition to clinical trial registration is unknown.
METHODS: Sixty-two Nephrology journals were selected through the 2021 Scopus CiteScore tool. Each journal\'s Instructions for Authors was assessed to determine endorsement of study design-specific reporting guidelines or clinical trial registration. Researchers used R (version 4.2.1) and RStudio to create data summaries of descriptive statistics for nephrology journal reporting guidelines.
RESULTS: Clinical trial registration was required by 52% (32/62) of nephrology journals within our sample. The reporting guideline for clinical trials, CONSORT, was required by 17.74% (11/62) of journals. The EQUATOR Network was mentioned by 46.77% (29/62) of journals, while 9.67% (6/62) failed to mention the ICMJE. The reporting guideline for systematic review, PRISMA, was only required by 12.90% (8/62) of journals. When contacting journal editors, 9.67% (6/62) responded and 4.83% (3/62) provided clarifying information.
CONCLUSIONS: Reporting guidelines and clinical trial registration are suboptimally required and recommended by nephrology journals. Their adoption may decrease bias and increase research quality. Thus, nephrology journals should consider a more complete endorsement of these safeguards.
BACKGROUND: Despite a rising disease burden, research published on chronic kidney disease (CKD) and the field of nephrology has failed to keep pace and is limited. To improve the quality of research in the field of nephrology, reporting guidelines have been developed to minimize such deficits in research quality. However, the extent to which nephrology journals require and use reporting guidelines in addition to clinical trial registration is unknown.
METHODS: Sixty-two Nephrology journals were selected through the 2021 Scopus CiteScore tool. Each journal\'s Instructions for Authors was assessed to determine endorsement of study design-specific reporting guidelines or clinical trial registration. Researchers used R (version 4.2.1) and RStudio to create data summaries of descriptive statistics for nephrology journal reporting guidelines.
RESULTS: Clinical trial registration was required by 52% (32/62) of nephrology journals within our sample. The reporting guideline for clinical trials, CONSORT, was required by 17.74% (11/62) of journals. The EQUATOR Network was mentioned by 46.77% (29/62) of journals, while 9.67% (6/62) failed to mention the ICMJE. The reporting guideline for systematic review, PRISMA, was only required by 12.90% (8/62) of journals. When contacting journal editors, 9.67% (6/62) responded and 4.83% (3/62) provided clarifying information.
CONCLUSIONS: Reporting guidelines and clinical trial registration are suboptimally required and recommended by nephrology journals. Their adoption may decrease bias and increase research quality. Thus, nephrology journals should consider a more complete endorsement of these safeguards.
摘要：
目的：确定肾脏病学期刊推荐和要求报告指南依从性和临床试验注册的程度。
背景：尽管疾病负担不断上升，发表在慢性肾脏病（CKD）和肾脏病领域的研究未能跟上步伐，并且受到限制。为了提高肾脏病学领域的研究质量，已经制定了报告指南，以最大程度地减少研究质量方面的缺陷。然而,除临床试验注册外,肾脏病学杂志在多大程度上要求和使用报告指南尚不清楚.
方法：通过2021年ScopusCiteScore工具选择了62种肾脏病学期刊。评估每个期刊的作者说明，以确定对研究设计特定报告指南或临床试验注册的认可。研究人员使用R（4.2.1版）和RStudio为肾脏病杂志报告指南创建描述性统计的数据摘要。
结果：我们样本中52%（32/62）的肾脏病学期刊要求临床试验注册。临床试验报告指南，CONSORT,17.74%(11/62)的期刊要求。46.77%(29/62)的期刊提到了EQUATOR网络，而9.67%(6/62)没有提到ICMJE。系统审查的报告指南，PRISMA,只有12.90%(8/62)的期刊需要。联系期刊编辑时，9.67%(6/62)回答，4.83%(3/62)提供澄清信息。
结论：肾脏病学期刊对报告指南和临床试验注册的要求并不理想。采用它们可以减少偏见并提高研究质量。因此，肾脏病学期刊应考虑更全面地认可这些保障措施。
背景：尽管疾病负担不断上升，发表在慢性肾脏病（CKD）和肾脏病领域的研究未能跟上步伐，并且受到限制。为了提高肾脏病学领域的研究质量，已经制定了报告指南，以最大程度地减少研究质量方面的缺陷。然而,除临床试验注册外,肾脏病学杂志在多大程度上要求和使用报告指南尚不清楚.
方法：通过2021年ScopusCiteScore工具选择了62种肾脏病学期刊。评估每个期刊的作者说明，以确定对研究设计特定报告指南或临床试验注册的认可。研究人员使用R（4.2.1版）和RStudio为肾脏病杂志报告指南创建描述性统计的数据摘要。
结果：我们样本中52%（32/62）的肾脏病学期刊要求临床试验注册。临床试验报告指南，CONSORT,17.74%(11/62)的期刊要求。46.77%(29/62)的期刊提到了EQUATOR网络，而9.67%(6/62)没有提到ICMJE。系统审查的报告指南，PRISMA,只有12.90%(8/62)的期刊需要。联系期刊编辑时，9.67%(6/62)回答，4.83%(3/62)提供澄清信息。
结论：肾脏病学期刊对报告指南和临床试验注册的要求并不理想。采用它们可以减少偏见并提高研究质量。因此，肾脏病学期刊应考虑更全面地认可这些保障措施。
